Pittkid, My main premise has always been that BP would be able to sell
Vascepa in far larger amounts and much sooner than what AMRN could ever
realistically do. BP knows how to market, sell, and distribute drugs.
They do that very well. Europe especially is the one place where BP
is needed. Why? They do not allow direct to consumer advertising there
and each country must be negotiated with individually with regard to
pricing. This is why a takeout by Novartis, Bayer, AZN, or Roche makes
so much sense. Partnering is a gamble as JT proved when he selected
the Japanese partner to sell Vascepa. BP will want to own AMRN because
they may want to do more with it and need all of the IP, patents, R&D,
etc. Despite all of "wailing and gnashing of teeth" over Du's ruling,
BP would come in and rev up sales...they would likely get a better
outcome on any appeal and are more likely to have their appeal heard.
If JT honestly believes he is the chosen one to build a BP by bringing
Vascepa to the masses, then he is delusional. (Sadly, he just might be.)
He has been blindsided to many times and it will not stop until AMRN
is owned by BP.
News 
Market Data 
Discover 
